From the Introduction: "The response to the COVID-19 [coronavirus disease 2019] pandemic has posed significant challenges for the U.S. blood supply. Mitigation strategies to prevent the spread of COVID-19, such as closures of schools and workplaces, have led to blood drive cancellations. In addition to blood drive cancellations, individual state stay-at-home orders and general fear of contracting the COVID-19 virus might dissuade individuals from scheduling appointments to donate blood. [...] This report provides a brief background of the regulatory framework for the U.S. blood supply, explains the federal response to the current crisis, and discusses potential treatment of COVID-19 using blood-derived products."
CRS Report for Congress, R46375
Congressional Research Service: https://crsreports.congress.gov/